Take a trial of UK to unlock this pageFind out more

Silence Therapeutics

SLN 115.25p 1.8  1.5%
11:29am 1.50k

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2010 2011 2012 2013 2014 2015 TTM 2016E 2017E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p -29.9%

FINANCIAL BRIEF: For the six months ended 30 June 2016, Silence Therapeutics plc revenues was not reported. Net loss increased 14% to L4.7M. Higher net loss reflects RNA therapeutics segment loss increase of 44% to L4.7M, Unallocated Items segment loss increase from L962K to L2M. Basic Earnings per Share excluding Extraordinary Items remained flat at -L0.07. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 30th Jun '16) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2016
31st Dec 2017

Price Target: 1.61
(+41.41% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
2 brokers Broker Consensus Trend
Broker Recommendations for Silence Therapeutics
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 1 0 0 1

Named Brokers and Analysts
Canaccord Genuity Howard Miller , Edison Investment Research Linda Pomeroy , N+1 Singer Jens Lindqvist , Chardan Capital Markets Madhu Kumar , Virtua Research (Historical) , and 1 unnamed other

Profile Summary

Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company's technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. The Company has a has a genetic toolkit with its own therapeutic payloads to modulate gene expression up as well as down in preclinical in vivo models, and delivery systems for various organs and cell types. The Company's RNA interference (RNAi) platform is AtuRNAi. AtuRNAi is based on specific small interfering RNA (siRNA) modules, stabilization technology and other tailored features. The Company's technology is in the clinic in a Phase IIa pancreatic cancer trial. The Company has developed modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutic RNA molecules.

Directors: Ali Mortazavi (CEO) , David Ellam (CFO) , Lars Karlsson (EDR) 54, Mark Cameron (OTH) , Stephen Parker (NEC) 57, Stuart Collinson (NED) 54, Alistair Gray (NED) 67,

No. of Employees: 56 No. of Shareholders: n/a

Last Annual December 31st, 2015
Last Interim June 30th, 2016
Incorporated November 18, 1994
Public Since January 5, 2010
Shares in Issue 69,801,624
Free Float 35.6m (51.0%)
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Eligible for an ISA? a SIPP?

SLN Share Price Performance SLNQuote
1.8  1.5%
Traded 11:29am · Minimum 15 min delayed · NMS: 1.50k

Latest SLN News Announcements (delayed)

Upcoming SLN Events

Recent ↓
Tuesday 27th September, 2016
Half Year 2016 Silence Therapeutics PLC Earnings Release
Wednesday 10th August, 2016
Silence Therapeutics PLC at Canaccord Genuity Growth Conference
Friday 17th June, 2016
Silence Therapeutics PLC Annual Shareholders Meeting
Tuesday 31st May, 2016 (estimate)
Silence Therapeutics PLC Annual Shareholders Meeting
Tuesday 5th April, 2016
Q4 2015 Silence Therapeutics PLC Earnings Release
Thursday 13th August, 2015
Silence Therapeutics PLC at Canaccord Genuity Growth Conference
Monday 1st June, 2015
Silence Therapeutics PLC Annual Shareholders Meeting
Tuesday 19th May, 2015
Silence Therapeutics PLC at Biocentury BioEquity Europe
Thursday 2nd April, 2015
Silence Therapeutics PLC Secondary Public Offering Pricing
Tuesday 16th September, 2014
Half Year 2014 Silence Therapeutics PLC Earnings Release
Friday 27th June, 2014
Silence Therapeutics PLC Annual Shareholders Meeting

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2016.

Should you buy SLN

Access SLN Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis